Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

[1]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[2]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[3]  C. Wellbrock,et al.  Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy , 2015, Pigment cell & melanoma research.

[4]  J. Massagué,et al.  Therapy-induced tumour secretomes promote resistance and tumour progression , 2015, Nature.

[5]  K. Flaherty,et al.  MITF Modulates Therapeutic Resistance through EGFR Signaling , 2015, The Journal of investigative dermatology.

[6]  M. Herlyn,et al.  A stress-induced early innate response causes multidrug tolerance in melanoma , 2015, Oncogene.

[7]  T. Graeber,et al.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.

[8]  N. Hayward,et al.  Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma , 2014, Nature Communications.

[9]  Kakajan Komurov,et al.  Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. , 2014, Cancer research.

[10]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[11]  Jun O. Liu,et al.  Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs , 2014, International journal of biological sciences.

[12]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[13]  G. Pupo,et al.  BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.

[14]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[15]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[16]  Rajiv Narayan,et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.

[17]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[18]  R. Ambinder,et al.  Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention , 2013, Current opinion in oncology.

[19]  K. Flaherty,et al.  BRAF in Melanoma: Current Strategies and Future Directions , 2013, Clinical Cancer Research.

[20]  Jason B. Lee,et al.  Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. , 2013, The Journal of clinical investigation.

[21]  Jun S. Song,et al.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.

[22]  Jun S. Song,et al.  BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.

[23]  M. Gore,et al.  Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.

[24]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[25]  R. Marais,et al.  Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma , 2012, Journal of the National Cancer Institute.

[26]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[27]  P. Frankel,et al.  Phase I study of nelfinavir in liposarcoma , 2012, Cancer Chemotherapy and Pharmacology.

[28]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[29]  Prahlad T. Ram,et al.  Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. , 2010, Cancer research.

[30]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[31]  S. Ishii,et al.  SKI knockdown inhibits human melanoma tumor growth in vivo , 2009, Pigment cell & melanoma research.

[32]  Walter Kolch,et al.  Cell fate decisions are specified by the dynamic ERK interactome , 2009, Nature Cell Biology.

[33]  Min Guan,et al.  Anti-HIV drugs for cancer therapeutics: back to the future? , 2009, The Lancet. Oncology.

[34]  D. Lang,et al.  Pigmentation PAX‐ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease , 2008, Pigment cell & melanoma research.

[35]  Yinshi Guo,et al.  Inhibition of PAX3 by TGF-beta modulates melanocyte viability. , 2008, Molecular cell.

[36]  Helen Pickersgill,et al.  Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF , 2008, PloS one.

[37]  Robert H. Shoemaker,et al.  Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo , 2007, Clinical Cancer Research.

[38]  S. Hahn,et al.  The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. , 2007, Neoplasia.

[39]  K. Flaherty,et al.  HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. , 2007, Cancer research.

[40]  P. Workman,et al.  Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. , 2005, Cancer research.

[41]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[42]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[43]  J. Campisi,et al.  Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Price,et al.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. , 2000, Genes & development.

[45]  D. Ho,et al.  A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. , 1998, The Journal of infectious diseases.